After stumbling on high investor expectations for its experimental hepatitis C therapy, telaprevir, Vertex garnered a dose of good news with the release of positive Phase IIa data on VX-770 for cystic ...
Last October, the U.S. Food and Drug Administration (FDA) approved Trikafta to treat cystic fibrosis (CF). The drug’s maker, Vertex Pharmaceuticals, was already riding high on clinical trial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results